03:14:27 EDT Sat 20 Apr 2024
Enter Symbol
or Name
USA
CA



V:CZO - Ceapro Inc. - http://www.ceapro.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CZO - V  492.50.24·0.2515.00.24-0.01-4.0178.942170.24  0.245  0.240.64  0.1515:54:05Mar 2815 min RT 2¢
TSX-V - V492.50.24·0.2515.00.245-0.005-2.03.0110.245  0.245  0.2450.64  0.1515:33:3715 min
NEO ATS - U 0.24-0.01-4.03.0120.24  0.24  0.2415:51:0615 min
Alpha - A 0.24-0.01-4.0127.03010.24  0.24  0.2415:47:2915 min
Omega - O 0.24-0.01-4.04.5130.24  0.24  0.2415:54:0515 min
Pure - P 0.24-0.01-4.040.0940.24  0.24  0.2415:54:0515 min
CX2 - H 0.24-0.01-4.00.5010.24  0.24  0.2409:49:0215 min
TriAct - M 0.250.95    Sep 08-2015 min

Recent Trades - Last 10 of 17
Time ETExPriceChangeVolumeBuyerSellerMarkers
15:54:05P0.24-0.0119,0001 Anonymous124 QuestradeK
15:54:05O0.24-0.011,0001 Anonymous124 QuestradeK
15:54:05M0.24-0.0118480 National Bank124 QuestradeE
15:51:44P0.24-0.0112,0001 Anonymous124 QuestradeK
15:51:44O0.24-0.011,5001 Anonymous124 QuestradeK
15:51:44M0.24-0.012502 RBC124 QuestradeE
15:51:06P0.24-0.013,0001 Anonymous124 QuestradeK
15:51:06O0.24-0.012,0001 Anonymous124 QuestradeK
15:51:06M0.24-0.012107 TD Sec124 QuestradeE
15:51:06U0.24-0.011,5002 RBC124 QuestradeK

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2024-03-28 11:36C:CZO0.235News ReleaseCeapro, Aeterna merger receives court approval
2024-03-12 14:33C:CZO0.23News ReleaseCeapro, Aeterna holders OK merger at March 3 meeting
2024-02-26 12:40C:CZO0.26News ReleaseAeterna, Ceapro receive proxy support for merger
2024-02-23 11:36C:CZO0.26News ReleaseCeapro talks Aeterna merger, operations update
2024-02-15 18:15C:CZO0.18News ReleaseCeapro mails information circular for March 12 meeting
2023-12-14 10:31C:CZO0.225Resume TradingCeapro to resume at 8 a.m. PT
2023-12-14 09:27C:CZO0.225News ReleaseAeterna Zentaris, Ceapro sign definitive merger deal
2023-12-14 07:57C:CZO0.225Halt TradingCeapro halted at the open
2023-12-13 13:21C:CZO0.23News ReleaseCeapro begins patient dosing in avenanthramides study
2023-11-29 14:59C:CZO0.24News ReleaseCeapro loses $1.04-million in Q3 2023
2023-11-29 09:03C:CZO0.25SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-11-29 09:03C:CZO0.25SEDAR Interim MD & ASEDAR Interim MD & A
2023-11-27 11:01C:CZO0.25News ReleaseCeapro begins study of avenanthramides for inflammation
2023-11-07 11:25C:CZO0.305News ReleaseCeapro, Natex to work on PGX tech development
2023-08-29 15:27C:CZONews ReleaseCeapro loses $1.15-million in Q2
2023-08-29 08:35C:CZO0.40SEDAR Interim MD & ASEDAR Interim MD & A
2023-08-29 08:01C:CZO0.40SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-08-25 09:38C:CZO0.44News ReleaseCeapro extends supply, distribution deal with Symrise
2023-07-18 15:30C:CZO0.43News ReleaseCeapro expands research work with Angiogenesis
2023-06-07 12:56C:CZO0.47News ReleaseCeapro shareholders approve all matters at AGSM